WallStreetZenWallStreetZen

NASDAQ: AVTE
Aerovate Therapeutics Inc Stock Forecast, Predictions & Price Target

Open Broker Account

Should I buy or sell AVTE stock?

Based on 1 analyst offering ratings for Aerovate Therapeutics Inc.
Hold
Strong Buy
0 analysts 0%
Buy
0 analysts 0%
Hold
1 analysts 100%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their AVTE stock forecasts and price targets.

AVTE stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
BTIG
Top 34%
67
HoldDowngradesN/AN/A2022-08-16

1 of 1

Forecast return on equity

Is AVTE forecast to generate an efficient return?
Company
-59.95%
Industry
14.69%
Market
64.75%
AVTE's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is AVTE forecast to generate an efficient return on assets?
Company
-56.49%
Industry
13.16%
AVTE is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

AVTE earnings per share forecast

What is AVTE's earnings per share in the next 3 years based on estimates from 3 analysts?
Avg 1 year Forecast
-$1.94
Avg 2 year Forecast
-$2.10
Avg 3 year Forecast
-$2.05

AVTE revenue forecast

What is AVTE's revenue in the next 3 years based on estimates from 1 analyst?
Avg 1 year Forecast
$36.7M
Avg 2 year Forecast
$129.1M
Avg 3 year Forecast
$323.8M

AVTE vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
AVTE$18.42N/AN/AHold
VERA$16.35$35.33+116.10%Strong Buy
NGM$5.56$12.00+115.83%Buy
ALXO$11.08$41.75+276.81%Strong Buy
TARS$16.90$40.00+136.69%Strong Buy

Aerovate Therapeutics Stock Forecast FAQ

Is Aerovate Therapeutics Stock a good buy in 2022, according to Wall Street analysts?

The consensus among 1 Wall Street analyst covering (NASDAQ: AVTE) stock is to Hold AVTE stock.

Out of 1 analyst, 0 (0%) are recommending AVTE as a Strong Buy, 0 (0%) are recommending AVTE as a Buy, 1 (100%) are recommending AVTE as a Hold, 0 (0%) are recommending AVTE as a Sell, and 0 (0%) are recommending AVTE as a Strong Sell.

If you're new to stock investing, here's how to buy Aerovate Therapeutics stock.

What is AVTE's Earnings Per Share (EPS) forecast for 2022-2024?

(NASDAQ: AVTE) Aerovate Therapeutics's current Earnings Per Share (EPS) is -$1.57. On average, analysts forecast that AVTE's EPS will be -$1.94 for 2022, with the lowest EPS forecast at -$1.95, and the highest EPS forecast at -$1.93. On average, analysts forecast that AVTE's EPS will be -$2.10 for 2023, with the lowest EPS forecast at -$2.21, and the highest EPS forecast at -$1.98. In 2024, AVTE's EPS is forecast to hit -$2.05 (min: -$2.11, max: -$1.98).

What is AVTE's forecast return on equity (ROE) for 2022-2025?

(NASDAQ: AVTE) forecast ROE is -59.95%, which is considered weak.

What is AVTE's earnings growth forecast for 2022-2024?

(NASDAQ: AVTE) Aerovate Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 7.86%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 16.96%.

Aerovate Therapeutics's earnings in 2022 is -$44,712,000.On average, 3 Wall Street analysts forecast AVTE's earnings for 2022 to be -$47,733,842, with the lowest AVTE earnings forecast at -$47,979,892, and the highest AVTE earnings forecast at -$47,487,791. On average, 3 Wall Street analysts forecast AVTE's earnings for 2023 to be -$51,670,653, with the lowest AVTE earnings forecast at -$54,377,211, and the highest AVTE earnings forecast at -$48,718,045.

In 2024, AVTE is forecast to generate -$50,440,400 in earnings, with the lowest earnings forecast at -$51,916,704 and the highest earnings forecast at -$48,718,045.

What is AVTE's revenue growth forecast for 2026-2028?

(NASDAQ: AVTE) Aerovate Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 24.9%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 6.76%.

Aerovate Therapeutics's revenue in 2022 is $0.On average, 1 Wall Street analysts forecast AVTE's revenue for 2026 to be $903,498,281, with the lowest AVTE revenue forecast at $903,498,281, and the highest AVTE revenue forecast at $903,498,281. On average, 2 Wall Street analysts forecast AVTE's revenue for 2027 to be $3,177,105,446, with the lowest AVTE revenue forecast at $2,338,958,239, and the highest AVTE revenue forecast at $4,015,277,258.

In 2028, AVTE is forecast to generate $7,966,138,434 in revenue, with the lowest revenue forecast at $4,005,213,783 and the highest revenue forecast at $11,927,063,086.

What is AVTE's forecast return on assets (ROA) for 2022-2025?

(NASDAQ: AVTE) forecast ROA is -56.49%, which is lower than the forecast US Biotechnology industry average of 13.16%.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.